PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $61,272,000 | -38.7% | 3,115,008 | 0.0% | 1.08% | -22.1% |
Q3 2021 | $99,992,000 | -5.2% | 3,115,008 | 0.0% | 1.39% | -18.1% |
Q2 2021 | $105,443,000 | -9.9% | 3,115,008 | 0.0% | 1.69% | -4.1% |
Q1 2021 | $117,000,000 | -7.9% | 3,115,008 | -18.6% | 1.76% | -0.7% |
Q4 2020 | $127,067,000 | -9.4% | 3,825,008 | 0.0% | 1.78% | -30.8% |
Q3 2020 | $140,263,000 | +11.4% | 3,825,008 | 0.0% | 2.57% | +4.6% |
Q2 2020 | $125,881,000 | +31.5% | 3,825,008 | +3.2% | 2.45% | -18.9% |
Q1 2020 | $95,725,000 | -15.7% | 3,707,408 | +1.7% | 3.02% | -12.2% |
Q4 2019 | $113,562,000 | – | 3,646,808 | – | 3.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |